J&J and BMS join the list of thought leaders speaking at Real Endpoints Symposium in November
08/16/2012

Steve Wooding, VP, Head of Market Access, EMEA, J&J, and
Ammar Qadan, Exec Dir - Diabetes Payer Marketing & Market Access Strategy USP, BMS to speak on "Payer-Pharma Risk-Sharing: The Only Plausible Near-Term Solution to The Value Problem" at RealEndpoints.com/Symposium

Online PR News – 16-August-2012 – Westport, CT – The compelling logic behind payer-pharma risk-shares have already made them a growing, if still small, component of European access strategies. As health care costs continue to soar, some form of risk sharing will have to be part of the solution in the US too. So which models work? And do they pave the way for more permanent value-based pricing?

Steve Wooding, VP, Head of Market Access, EMEA, Johnson & Johnson and
Ammar Qadan, Executive Director - Diabetes Payer Marketing & Market Access Strategy USP, Bristol Myers Squibb will be joined by Michael Sherman, MD, CMO, Harvard Pilgrim and Melanie Senior, Sr. Analyst, Real Endpoints to discuss "Payer-Pharma Risk-Sharing: The Only Plausible Near-Term Solution to The Value Problem".

Risk-Sharing along with Bundling, Comparative effectiveness, Pathways, Real world evidence and Adherence are just some of the many disruptors changing how innovation is valued. Hear about these and more at The Real Endpoints Symposium, Nov 1-2, 2012. www.realendpoints.com/symposium